Oral cholera vaccine - 86% effectiveness in epidemic situations
The IVI-developed oral cholera vaccine (Shanchol™) has been proven effective against cholera in epidemic situations. In a recently released study by Epicentre, the research division at Medecins Sans Frontieres and the Guinean Ministry of Health looked at how the oral cholera vaccine (OCV) would work in an already epidemic situation and found that it provided 86% effectiveness against cholera. These results are a major boost in the global health artillery in controlling cholera, a disease which affects 3 to 5 million people a year and kills 100,000 to 130,000 annually.
IVI’s OCV five-year efficacy results from a phase 3 clinical trial were published in The Lancet this past October. Find it here: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)62167-4/abstract#cor1
The MSF study was published in The New England Journal of Medicine: http://www.nejm.org/doi/full/10.1056/NEJMoa1312680#t=articleBackground
For more information on IVI’s Cholera program, please visit the CIVI homepage at: http://civi.ivi.int/